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9Long-term Outcomes of Kidney Transplantation in
Fabry Disease
Sara Ersözlü, MD,1,2 Robert J. Desnick, MD, PhD,3 Uyen Huynh-Do, MD,4 Sima Canaan-Kühl, MD,5
Frédéric Barbey, MD,6 Vera Genitsch, MD,7 Thomas F. Mueller, MD,8 Marcus Cheetham, PhD,2
Andreas J. Flammer, MD,9 Stefan Schaub, MD,10 and Albina Nowak, MD2,9
Background. Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A
gene that obliterate or markedly reduce α-galactosidase A activity. This results in the systemic accumulation of its
glycosphingolipid substrates in body fluids and organs, including the kidney. Fabry nephropathy can lead to end-stage renal dis-
ease requiring kidney transplantation. Little is known about its long-term outcomes and the overall patient survival after
kidney transplantation.Methods.Here, we report 17 Fabry patients (15 male and 2 female subjects) who received kidney trans-
plants and their long-term treatment and follow-up at 4 specialized Fabry centers.Results. The posttransplant follow-up ranged
to 25 years, with a median of 11.5 (range, 0.8-25.5] years. Graft survival was similar, and death-censored graft survival was supe-
rior to matched controls. Fabry patients died with functioning kidneys, mostly from cardiac causes. In 2 male subjects 14 and
23 years posttransplant, the grafts had a few typical FD lamellar inclusions, presumably originating from invading host macro-
phages and vascular endothelial cells. Conclusions.We conclude that kidney transplantation has an excellent long-term out-
come in FD.
(Transplantation 2018;102: 1924–1933)Fabry disease (FD), a rare X-linked lysosomal storage dis-order, is caused by mutations in the α-galactosidase A
gene (GLA).1 The mutations result in markedly decreased
or absent α-galactosidase A (α-Gal A) enzymatic activity and
the accumulation of itsmajor substrate, globotriaosylceramide
(Gb3), and its deacylated derivative, globotriaosylsphingosine
(Lyso-Gb3)2 in the fluids and cellular lysosomes throughout
the body. Progressive Gb3 accumulation causes major organ
damage, most frequently of the kidneys and heart.1
There are 2 major subtypes: the “classic” and “later-
onset” phenotype. Classic male subjects have little or no re-
sidual α-Gal A activity; have prominent vascular endothelial
cell glycosphingolipid accumulation; and have childhood orReceived 20 November 2017. Revision received 17 March 2018.
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Copyright © 2018 Wolters Kluweradolescence onset of severe acroparesthesias, angiokeratoma,
hypohidrosis, and corneal and lenticular opacities that, with
age, progress to early demise primarily due to cardiac and
renal involvement.3,4 Male subjects with the later-onset phe-
notype have residual α-Gal A activity; have no vascular endo-
thelial cell glycosphingolipid accumulation; lack the childhood/
adolescent hallmark symptoms; and predominantly experi-
ence progressive nephropathy, cardiomyopathy, and cere-
brovascular disease in adulthood.5-7 Heterozygous female
subjects also can be affected by the disease; however, their
FD manifestations are variable and typically milder because
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TABLE 1.
The matching algorithm of FD and non-FD recipients
Parameter Deviation
Sex —
↓
Year of transplantation ±3 years
↓
Age at transplantation −2/+4 years
↓
Number of transplants —
↓
Presence of DSA —
↓
HLA mismatches ±2
↓
Immunosuppression era ±1
↓
Immunosuppression drugs max. 1 drug
DSA, donor-specific anti-HLA antibodies; HLA, human leukocyte antigen; max, maximum.
© 2018 Wolters Kluwer Ersözlü et al 1925This means that Fabry nephropathy can lead to end-stage
renal disease (ESRD) requiring dialysis or transplantation
(KTx) in male subjects and severely affected heterozygotes
with both phenotypes.4,10,11 The first kidney transplant in an
FD patient was conducted in 1967 in Basel, Switzerland.12
Initial reports advised against KTx in FD because of infec-
tious and other complications and early transplant demise.13
Limited information is available about the long-term outcome
of KTx in FD, particularly posttransplant survival.14-16 Later
studies showed good survival rates, but mortality rates were
high compared with non-Fabry recipients, mainly because
of cardiovascular events.16 The longest previously reported
graft survival was 10 years,14-18 and most patient outcome
studies were conducted before the introduction of enzyme re-
placement therapy (ERT)14-17 or did not include data on the
duration of and the number of patients undergoing ERT.15,16
Moreover, previous studies, most of which were registry
analyses, did not reportGLAmutations of recipients to con-
firm the FD diagnosis and determine the phenotypic subtype
nor were systematic transplant biopsies performed.14-18 The
impact of posttransplantation ERTwas also unclear. Because
the normal endogenous α-Gal A activity in the graft should
be sufficient for graft health, the recently reported European
Best Practice Guideline on Fabry nephropathy recommended
that ERT should be continued for nonrenal indications.19
Some early reports, particularly before the advent of ERT,
found Gb3 deposits in kidney transplants, albeit in host
macrophages or vascular endothelial cells that infiltrated
the allograft.20-23 To further document the effects of renal
transplants in FD, we conducted a long-term observational
study that included follow-upofKTx grafts for up to 25 years
in 17 Fabry patients, who were regularly treated and followed
at 4 specialized FD centers.
MATERIALS AND METHODS
We investigated the FD patients that were transplanted
and followed in Zurich, Bern, and Lausanne, Switzerland,
and in Berlin, Germany. This study was conducted in accor-
dance with the Declarations of Helsinki and Istanbul and ap-
proved by the respective center’s ethics committee (KEK-ZH-Nr.
2014–0534, PB_2016–00360, and EKNZ 2015–403). All
living patients provided written informed consent.
Patient Selection, Characteristics, and Follow-up
The databases of all participating centers were screened for
patients with FD and kidney transplantation, and all identi-
fied patientswere included in the study. The patients (15male
and 2 female subjects) were all regularly treated between
1979 and March 2017 at the 4 specialized FD centers in
Zurich (patients 1-9), Bern (patients 10-12), Lausanne (pa-
tient 17), and Berlin (patients 13-16). The clinical data were
extracted from medical records. Phenotyping was deter-
mined as reported previously.24 Separate annual follow-ups
were carried out in the Fabry and transplant centers. ERT
was initiated according to the written local guidelines. Ac-
cordingly, ERT was indicated in all male subjects, indepen-
dent from age, phenotype, and symptoms. In heterozygotes,
ERT was indicated if they had proteinuria of more than
300 mg per day, Fabry-typical kidney biopsy findings, signs
of Fabry cardiomyopathy such as left ventricular hypertro-
phy or arrhythmia, stroke or transient ischemic attack, per-
sistent FD-related neuropathic pains despite conventionalCopyright © 2018 Wolters Kluwer Hanalgetic therapy, and/or gastrointestinal symptoms. ERT
was prescribed at the licensed dose of either 0.2 mg/kg body
weight of recombinant agalsidase-alpha (Replagal) or 1mg/kg
body weight agalsidase-beta (Fabrazyme) and given intrave-
nously every 14 days.
Endpoint Evaluation
Cumulative patient and graft survival and death-censored
graft survival were determined. Transplant function was reg-
ularly monitored at the respective FD and transplant centers.
If a patient died outside the Fabry center, the date of death
was obtained from the patient’s general practitioner, family,
or home care nurse administering ERT. All events were pro-
spectively recorded and coded. The follow-up timewas based
on the date of the patient’s death, graft loss, or the end of the
study (March 31, 2017). Graft survival analysis was used to
estimate the probability of a functioning graft at the study
end. Graft failure was defined as graft loss or patient death,
whichever came first. In addition, death-censored graft sur-
vival was used to estimate the probability of graft loss irre-
spective of death. For this purpose, the date of death in
patients who died with a functioning graft was defined as
the last follow-up.25
Control Group and Matching Algorithm
Data from non-FD KTx recipients were from the kidney
transplant registry of the University Hospital Basel Switzerland
and served as the control group.26 This registry contains
detailed information on more than 2220 kidney transplant
patients, grouped according to immunosuppression era, as
previously published byWehmeier et al., 2016, and classified
as follows: first period 1967 to 1980, second period 1981 to
1997, third period 1998 to 2004, and fourth period 2005
to 2015.26
To compare graft survival and overall patient survival be-
tween FD andmatched non-FDKTx controls, each FD recip-
ient was best matched and blinded to the outcome in a 1:1
ratio. The matching algorithm is shown in Table 1. The FD
and non-FD KTx recipients were matched for sex, number
of transplants, similar age with a maximum of −2/+4 years,
and KTx year ±3 years, similar number of human leukocyteealth, Inc. All rights reserved.
1926 Transplantation ■ November 2018 ■ Volume 102 ■ Number 11 www.transplantjournal.comantigen (HLA) mismatches ±2, same status of donor-specific
antigens (DSAs), belonged to the same immunosuppression
period (when possible), and similar immunosuppression re-
gime with a maximum of 1 drug difference (Table 2). A 1:1
matching ratio was preferred to 1:2 or 1:3 as it would have
required further expansion of the matching criteria to find
several matches for 1 patient.
KTx Outcome and Gb3 Depositions
The latest value of serum creatinine (μmol/L), estimated
glomerular filtration rate (eGFR) calculated according to the
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation,27 urinary protein/creatinine (mg/mmol), and
albumin/creatinine (mg/mmol) ratios were used to assess
KTx function. An eGFR below 15 mL/min per 1.73m2 was
considered a transplant failure. Recurrence of Gb3 deposits
in kidney transplants was assessed using electronmicroscopyTABLE 2.
Demographics, donor type, baseline immunogenic risk, and clini
Cause of ESRD Sex Age at KTx Year of KTx Donor
FD (1) m 24 2005 Livin
Interstitial nephropathy 26 2002 Livin
FD (2) m 40 1995 Decea
Extracapillary glomerulonephritis type II 41 1993 Livin
FD (3) m 45 1993 Decea
Polycystic kidney disease 45 1994 Livin
FD (4) m 61 2007 Decea
Hypertensive nephropathy 61 2007 Decea
FD (5a)a m 44 1999 Decease
Diabetic nephropathy 46 1999 Living
FD (5b)b m 56 2011 Deceased
Polycystic kidney disease 57 2010 Deceased
FD (6) M 44 2011 Decea
Malignant nephrosclerosis 42 2010 Decea
FD (7) m 17 1991 Livin
Chronic pyelonephritis 18 1990 Livin
FD (8) m 35 1993 Decea
Chronic pyelonephritis due to VUR 34 1993 Decea
FD (9) m 33 1979 Decea
Polycystic kidney disease 35 1977 Decea
FD (10) m 28 1990 Decea
Chronic pyelonephritis due to VUR 28 1992 Livin
FD (11) m 44 2014 Livin
Diabetic nephropathy 42 2014 Livin
FD (12) m 27 1998 Decea
Chronic pyelonephritis 28 1997 Livin
FD (13) m 53 2006 Livin
Hypertensive nephropathy 52 2004 Livin
FD (14) f 56 2016 Livin
Polycystic kidney disease 57 2015 Livin
FD (15) m 16 2013 Livin
Congenital anomalies of the kidney 20 2011 Livin
FD (16) f 45 2015 Decea
Unknown 44 2015 Decea
FD (17) m 59 2002 Decea
Chronic glomerulonephritis 56 2002 Decea
aFirst and bsecond transplant in the same FD recipient. A, azathioprine; C, cyclosporine; DSA, donor-specif
kocyte antigen; KTx, kidney transplant; m, male; M, mycophenolate; P, prednisone; T, tacrolimus; VUR, ve
Copyright © 2018 Wolters Kluwer(EM) and/or histological analysis of kidney tissue from biop-
sies or autopsies.
Statistical Analysis
Continuous variables were expressed as medians with in-
terquartile ranges. Kaplan-Meier analysis and log-rank test
of survival distributions were calculated. The statistical anal-
yses were performed using the SPSS/PC software package
(version 23.0; SPSS Inc., Chicago, IL). All statistical tests
were 2 sided, and P<0.05 were considered significant.RESULTS
Patients
The patients’ demographics, renal data, and KTx-related
information are presented in Table 2, and detailed clinical in-
formation, GLA genotypes, phenotypes, age at death, andcal outcomes in FD recipients and matched non-FD controls
type
Number of HLA
mismatches
Presence
of DSA
Baseline
immunosuppression Graft loss Death
g 5 No M, P, C No No
g 3 M, P, C No No
sed 3 No A, P, C No Yes
g 3 A, P, C Yes No
sed 4 No A, P, C No No
g 3 A, P, C No No
sed 4 No M, P, C No No
sed 4 M, P, T No No
d (first) 3 No M, P, C Yes Yes
(first) 3 M, P, C Yes No
(second) 2 Yes M, P, C No Yes
(second) 3 M, P, T No No
sed 4 No M, P, C No No
sed 5 M, P, T Yes No
g 2 No A, P, C Yes No
g 2 A, P, C Yes No
sed 4 No P, C No Yes
sed 3 A, P, C Yes No
sed 4 No A, P No Yes
sed 5 A, P Yes No
sed 3 No A, P, C No Yes
g 2 A, P, C Yes Yes
g 2 No M, P, T No No
g 1 M, P, T No No
sed 3 No M, P, C No No
g 3 M, P, C Yes No
g 3 No M, P, C No No
g 3 M, P, C No No
g 4 No M, P, T No No
g 5 M, P, T No No
g 3 No M, P, T No No
g 3 M, P, T No No
sed 0 No M, P, T No No
sed 1 M, P, T No No
sed 3 No M, P, C No Yes
sed 2 M, P, C Yes Yes
ic anti-HLA antibodies; ESRD, end stage renal disease; FD, Fabry disease; f, female; HLA, human leu-
sicoureteral reflux.
 Health, Inc. All rights reserved.
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1928 Transplantation ■ November 2018 ■ Volume 102 ■ Number 11 www.transplantjournal.comcause are presented in Tables 3 and 4. There were 14 affected
classic male subjects and 1 male subject with the later-onset
phenotype who were diagnosed with FD at median ages of
34 (21-43) and 49 years, respectively. In addition, there were
2 severely affected heterozygotes, both from classically af-
fected families, who were diagnosed at ages 38 and 54 years.
The 15 male and 2 female patients were treated and followed
for up to 25 years, with a median patient age of 53 (45-60)
years as of March 31, 2017, or at death. In the majority, ne-
phropathy was first diagnosed at ESRD, which then led to
the diagnosis of FD. Diagnosis of nephropathy in the classi-
cally affected male subjects was made at the median age of
31 (21-43) years, in the later-onset male subject at 49 years,
and at 25 and 42 years in the 2 heterozygotes. Chronic dial-
ysis was initiated at a median age of 33 (22-43) years in
the classically affected male subjects and at 38 years in 1 het-
erozygote and continued for a median time of 1 (0.25-3.7)
years before KTx was undertaken at the median age of
44 (28-47) years. Eleven patients received 12 kidneys from
deceased and 6 patients from living donors. The living
donors were 2 healthy fathers (both to male recipients),
1 mother (who was diagnosed with FD after donating the
kidney to her undiagnosed son), 1 stepmother, and 2 spouses.
Immunosuppression was prescribed according to local trans-
plantation guidelines of the respective period.26 In this co-
hort, 5 patients were siblings belonging to 2 families with
the classic phenotype. Recipients in family 1 included males
7 and 12 and family 2 included males 8, 9, and 10.
Enzyme Replacement Therapy
Fourteen of the transplanted FD patients had ERT: 9 patients
started before and continued after KTx (4 agalsidase-α,
5 agalsidase-β) and 6 started after KTx (5 agalsidase-α,
1 agalsidase-β). Patient 5, who received 2 transplants, wasTABLE 4.
Transplant-related information in the FD recipients
Patient
Age at
KTx, yr
Year
of KTx
Survival
of KTx, yr
Donor type and HLA
mismatches
Immunosupp
at baseline
1 24 2005 11.2 Living (step mother) 5 M, P, C
2 40 1995 19.6 Deceased 3 A, P, C
3 45 1993 15.4 Deceased 4 A, P, C
4 61 2007 9.4 Deceased 4 M, P, C
5a 44 1999 9.1 Deceased (first) 3 M, P, C
5b 56 2011 3.2 Deceased(second) 2 M, P, C
6 44 2011 5.3 Deceased 3 M, P, C
7 17 1991 21.8 Living (father) 2 A, P, C
8 35 1993 22.6 Deceased 4 P, C
9 33 1979 13.8 Deceased 1 A, P
10 28 1990 11.6 Deceased 3 A, P, C
11 44 2014 3 Living (father) 3 M, P, T
12 27 1998 18.8 Deceased 2 M, P, C
13 53 2006 10.8 Living (wife) 3 M, P, C
14 56 2016 0.8 Living (husband) 4 M, P, T
15 16 2013 3.6 Living (mother) 3 M, P, T
16 45 2015 1.3 Deceased 0 M, P, T
17 59 2002 10.6 Deceased 3 M, P, C
aAt the end of follow-up time or latest available results. A, azathioprine; Alb/C, albumin/creatinine; C, cycl
Copyright © 2018 Wolters Kluwercounted in both categories. Their individual estimated cumu-
lative agalsidase doses after KTx are indicated in Table 3. Pa-
tient 9 died in the pre-ERT era. Patient 10 died shortly after
ERT became available. ERT was not provided to patient 3
because of the patient’s frailty and dementia.
Patient and Graft Survival
During the median overall follow-up time of 11.5 years
(range, 0.8-25.5), 11.6 years (7.6-17.1) for classic male sub-
jects, 9.4 years for the later-onset male subject, and 0.8 and
1.3 years for the 2 heterozygotes. Seven classic male subjects
died with functioning renal grafts (Table 3). The median age
at death was 59 (47-61) years. Four of the 7 male deaths re-
sulted from cardiac arrest secondary to hypertrophic cardio-
myopathy and ventricular arrhythmias (in 2 cases, most
likely triggered by septic endocarditis or hepatitis B), 1 died
from a brain stem compression due to a large basilar artery an-
eurysm, 1 committed suicide, and 1 cause remains unknown
(presumably cardiac due to known arrhythmias). The cumula-
tive FD patient survival with KTx is shown in Figure 1.
Cumulative graft survival in FD patients was similar to that
of matched controls (Figure 2). Two kidney transplants were
lost because of chronic transplant failure, (patients 5 and 7 af-
ter 9 and 22 years, respectively). Patient 5 was retransplanted
at 9.1 years, and patient 7 was on the transplant waiting list at
the end of this study. However, cumulative death-censored
graft survival in FD patients was better than that of matched
controls (P=0.03; Figure 3). As noted previously, FD patients
mainly died from cardiac events but with functioning grafts.
Overall patient and graft survival is shown in Table 5. There
were 10 patients who had functioning grafts 10 years post-
KTx that were all classic male subjects. Of the 10 patients
who had functioning transplants at 10 years post-KTx, the
median survival was 14.6 (11.1-20.2) years.ression
at last
eGFR
(mL/min)a
Serum
creatinine
(μmol/L)a
Pro/C ratio
(mg/mmol)a
Alb/C ratio
(mg/mmol)a
AT1-/ACE-
inhibitorsa
M, T 60 132 91 53.2 0
M, C 56 120 31 n/a 0
A, C 56 97 20 n/a 1
M, C 18 295 21 11.5 0
M, C anuric 0
M, C 42 154 22 9.3 0
M, C 77 99 no 4.3 1
P anuric 1
P, C 43 152 45 18.9 1
A, P n/a n/a n/a n/a n/a
A, P, C 27 282 109 n/a 1
M, T 55 132 7 0.8 1
M, C 49 147 9 2.4 0
M, P, T 63 101 no 0.4 1
M, P, T 74 77 9.2 0.3 1
M, T 98 96 9.8 0.8 1
M, P, T 49 115 7.8 0.2 0
M, C 68 96 29 1.1 1
osporine; M, mycophenolate; P, prednisone; Pro/C, protein/creatinine; T, tacrolimus.
 Health, Inc. All rights reserved.
FIGURE 1. Cumulative survival of FD patients after KTx. Cumulative
patient survival (Kaplan-Meier estimates) is shown for all FD patients
after kidney transplantation (n = 17). The median age at the end of
the study was 53 (45-60) years. Seven patients, all classic male sub-
jects, died at a median age of 59 (47-61) years.
FIGURE 3. Death-censored graft survival in FD patients and
matched controls. Cumulative death-censored graft survival is
shown in FD patients and matched controls. Death-censored graft
survival analysis is shown to be superior in Fabry patients, whomainly
died with functioning kidneys, mostly from cardiac causes.
© 2018 Wolters Kluwer Ersözlü et al 1929Kidney Transplant Biopsies
Twenty KTx biopsies were performed in 11 patients
(Table 6). There were 4 patients with graft biopsies after at
least 10 years (patients 7-10; biopsy after 11.6-22.6 years).
There was no evidence of glycosphingolipid deposits in the
transplanted kidneys with 2 exceptions among these patients
(patients 8 and 9). A few electron-dense lamellar inclusions
were identified in vascular endothelial cells in a classic male
14 years posttransplant (Figure 4, patient 9).28 The invasion
of vascular endothelial host cells into the graft endothelium
can occur.23 This recipient was not on ERTas he died before
it was available. The deceased donor of this recipient was a
35-year-old unrelated man. The other transplant recipient
with ultrastructural deposits appearing as “zebra bodies”
was the younger brother of the above patient (patient 8).
He was transplanted 14 years before ERT was available;FIGURE 2. Cumulative graft survival in FD patients and matched
controls. Cumulative graft survival is shown in FD patients and
matched controls. Graft survival analysis was censored at graft loss
or patient death, whichever came first. Graft survival is shown to be
similar in FD patients and matched controls.
Copyright © 2018 Wolters Kluwer Hsubsequently, he received ERT for 9 years, after which EM
showed a few myelin figures, most likely originating from
host histiocytes (Figure 5). In contrast, patient 7 (no ERT
for 10 years, biopsy after 21.8 years) and patient 10 (no
ERTat all, biopsy after 11.6 years) had noGb3 deposits. Also
in the other biopsies, no FD-specific changes were found on
light and/or EM.
DISCUSSION
In this study, we found similar overall and superior death-
censored graft survival in the FD patients compared with
non-FD matched controls. To our knowledge, these data de-
scribe the longest reported experience with KTx in FD—up
to 25 years. All of the KTx recipients in our cohort who died
were classic male subjects (median age at death, 59 years),
who had functioning grafts, their deaths mainly due to car-
diac events. Therefore, these findings highlight the importance
of cardiovascular protection and ERT in this population.
ERT should be beneficial in the long-term outcome of KTx
patients, by treating the heart and clearing other host cells
that canmigrate into the graft includingmacrophages, histio-
cytes, and vascular endothelial cells.29 The recipients’ sur-
vival rates were similar to non-FD recipients. Importantly,
our high-risk population of predominantly classic male sub-
jects, with most on ERT, survived longer (median age at
death, 59 years) than reported for an FD male population
without ERT (mean age at death, 49.9 years).3TABLE 5.
Patient and graft survival at 5, 10, 15, 18, and 20 years
Follow-up
time, yr
Number
of patients
Number
of grafts Patient survival Graft survival
5 13 14 100% (13/13) 93% (13/14)
10 11 12 100% (11/11) 92% (11/12)
15 9 10 67% (6/9) 60% (6/10)
18 9 10 44% (4/9) 40% (4/10)
20 8 9 25% (2/8) 22% (2/9)
ealth, Inc. All rights reserved.
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FIGURE 4. Electron microscopy of a kidney transplant 14 years
without ERT. Formalin fixed and refixed in glutaraldehyde. Vascular
endothelial cells showing numerous lamellar bodies in a patient with
the mutation p.V390CfsX9. (EM x 3700, inset x 83 700). Previously
published in Gantenbein et al., 1995 (Recurrence of Fabry’s disease
in a renal allograft 14 years after transplantation. Nephrol Dial Trans-
plant. 1995;10(2):287-9), with permission.28
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Copyright © 2018 Wolters KluwerSeveral case reports of KTx in FD (Table 7) and a few registry
studies14,16,18 have been published in the last 40 years, but all
had shorter follow-up periods. With findings similar to ours,
previous studies14-16 show patient and graft survival compa-
rable to non-FD patients and found cardiac and cardiovascu-
lar events as major causes of mortality in FD patients.
However, patient and graft survival rates in our patients were
superior to the rates reported in studies from the pre-ERTera:
the 10-year patient and graft survival in the present study ex-
ceeds 90%, previous studies report 67% to 76% patient and
56% to 67% graft survival.14,15
KTx remains an important therapeutic option for Fabry
nephropathy because ERT, when initiated late in the disease
course, only slows progression.24,30,31 Germain et al. re-
ported that patients who initiated treatment at older ages or
had advanced renal disease or both experienced faster disease
progression.32 The mean slope for eGFR for the 20 older pa-
tients (median age, 38 years) with urinary protein/creatinine
ratio of greater than 0.5 g/g or 50% or greater sclerotic glomer-
uli was −6.82 mL/min per 1.73m2/year.32 In contrast, the mean
slope for eGFR for the 32 younger patients (median age,
25 years) with urinary protein/creatinine ratio of less than
0.5 g/g or 50% or less sclerotic glomeruli was −1.89 mL/min
per 1.73 m2/year. In addition, the 3- to 5-year survival rate
of FD patients on chronic dialysis was less than that of the
general dialysis population.33,34 Unfortunately, there are no
comparative age-matched Fabry data for our sample from
Switzerland and Germany that could serve as the denomina-
tor. The survival data of our transplanted Fabry patients can
be compared with those of Fabry patients who underwent re-
nal dialysis approximately 20 to 25 years ago. Thadhani
et al.34 (2002) analyzed 137 FD patients in 2 cohorts, 1985
to 1993 (93 patients) and 1995 to 1998 (42 patients). Al-
though not age matched, the overall 3-year survival rate for
the 1985 to 1993 and 1995 to 1998 groups was 63% and
53%, respectively. Tsakiris et al.33 (1996) reported that the Health, Inc. All rights reserved.
FIGURE 5. Electron microscopic findings of a kidney transplant biopsy in a recipient with FD 14 years without ERT. Single inclusions with
lamellated structures—myeloid body—in a histiocyte, migrated into the graft vascular endothelium (A) (TEM, 2800) and in a histiocyte, inter-
calated into a graft podocyte (C). B and D, Higher magnification of the myeloid bodies showing the included storage material.
© 2018 Wolters Kluwer Ersözlü et al 19315-year survival rate of 83 Fabry dialysis patients reported
to the European Registry, who initiated dialysis from 1985
to 1993, was only 41%. Our findings that transplantation
offers longer survival rates would support the recommenda-
tion that all transplantable patients with suitable donors
(living-related or histocompatible) should be transplanted
when possible.
In our cohort, only 2 grafts in classic male brothers had re-
nal lysosomal substrate inclusions on EM. Lamellar lyso-
somal inclusions were present in vascular endothelial cells
of the older brother 13.8 years post-KTx (pre-ERT era), pre-
sumably because of the endothelial cell invasion from the
host into the graft.23 In his younger transplanted brother
who began ERT 14.3 years posttransplant and was biopsied
22.7 years after KTx, biopsy showed isolated inclusions in
histiocytes, which also migrated into the transplant from
the host. In contrast to these patients, 2 other patients, who
were also not under ERT for a long time (10 and 11.6 years)
and were biopsied after 11.6 and 21.8 years had no lyso-
somal inclusions by light and EM.TABLE 7.
Case reports of kidney biopsies from the pre-ERT era
Year of publication Authors Time point of microscopy
1972 Clarke et al.20 7 months (autopsy) EM: intra
1973 Bühler et al.12 17 months (autopsy) No depo
1981 Faraggiana et al.21 6 months LM: glom
EM: few
1982 Clement et al.35 15 months (autopsy) LM and
1982 Bannwart et al.36 12 yrs LM and
1986 McMahon et al.23 4 yrs Accumu
1987 Friedlaender et al.22 8 yrs LM: no a
EM: occ
1987 Popli et al.37 5.5 yrs donor w
LM and
1991 Mosnier et al.38 11 yrs (autopsy) LM: norm
EM: sph
1995 Gantenbein et al.28 14 yrs (autopsy) LM: no a
EM: mas
1998 Erten et al.39 10 yrs LM and
EM, electron microscopy; FD, Fabry disease; LM, light microscopy.
Copyright © 2018 Wolters Kluwer HAn important differential diagnosis in the interpretation of
the myelin figures and zebra bodies found in renal biopsies
are drug-induced phenocopies of FD1—ultrastructural changes
that appear morphologically similar to those due to FD.40-43
Certain cationic amphiphilic drugs and their derivates are inhib-
itors of α-Gal A and can cause renal inclusions which appear
similar to FD inclusions and are reversible after discontinua-
tion40: (hydro)-chloroquine43-45 and amiodarone46,47 are direct
inhibitors of α-Gal A, and gentamicin,40 ranolazine,48 pentam-
idine,49 and macrolide50 also cause the phenotype. Silicosis
results in inclusions that mimic those in FD, and thus, similar
observations were made in silica-induced nephropathy.1,51
Early studies reported increased levels of plasmaα-GalAactiv-
ity post-KTx20,52whichwere later shown to be due to increased
α-N-acetylgalactosaminidase (α-Gal B) activity, an enzyme evo-
lutionarily related toα-GalA,53,54 that is assayedusing the same
fluorogenic substrate. Thus, the increased α-Gal A activity was
an artifact. Subsequently, one of the authors (R.J.D.) showed
that plasmaα-Gal B activitywas increased because of the immu-
nosuppression medications (R.J.D., unpublished data, 1973).Histological findings
cellular multilamellar bodies, epithelium was normal; no accumulation of glycolipids
sits
erular, tubular and interstitial deposits
inclusions on the vascular endothelium
EM: normal
EM: normal
lation in endothelial cells leading to narrowing and occlusions
bnormalities
asional small myelin figures in the vascular endothelium
as heterozygous sister
EM: FD typical changes
al
ingolipid inclusions in the vascular endothelium
bnormalities
sive tubular, interstitial and endothelial deposits of Gb3
EM: normal
ealth, Inc. All rights reserved.
1932 Transplantation ■ November 2018 ■ Volume 102 ■ Number 11 www.transplantjournal.comImportantly, FD does not recur in kidney transplants, in
contrast to other renal diseases.55 Among hereditary systemic
diseases, primaryhyperoxaluria type1or adenine phosphoribosyl
transferase deficiency have high recurrence rates of renal dis-
ease in the transplant.55,56 In cystinosis, cysteine-laden cells
were occasionally observed in the grafts but were found to be
without clinical relevance.55 In Alport syndrome, antiglomerular
basement membrane antibodies were occasionally found.55
Primary renal diseases that recur in the transplant include
membranoproliferative glomerulonephritis (approximately
30% in type 1, 80% in type 2),55 focal segmental glomerulo-
sclerosis (30%-50%),57 and IgA nephropathy (50%).55 This
is not the experience in FD: if the graft is healthy, it can func-
tion well for at least 25 years as documented here.
Specific challenges of KTx in FD should be noted. Recipi-
ents or donors might have undiagnosed FD because FD is
not part of the routine pretransplant workups.58 Individuals
with unrecognized FDmay donate their kidneys to non-Fabry
patients (e.g.,58), which can lead to early graft dysfunction and
chronic kidney disease in the living donor and recipient.33
Living kidney donations can occur within families with un-
recognized FD relatives.37,59 Thus, it is important to perform
genetic testing for FD where there is clinical suspicion of FD
or an unclear nephropathy.
A limitation of this report is the size of the patient sample.
This is an inherent limitation in rare diseases. Moreover, we
might be analyzing survivor advantage, as Fabry patients
may not reach transplantation, especially in the era of late di-
agnosis. Furthermore, we have no way to determine, if all
Fabry patients were diagnosed pretransplant. There could
have been unrecognized Fabry patients with kidney trans-
plantation inwhom the diagnosis of FDwas not made. How-
ever, and in contrast to previous KTx reports,14,16,18 most
patients had a graft biopsy, and the majority had biopsy or
autopsy EM to exclude Gb3 deposits in the graft. EM was
not conducted in some of the donor kidneys because the de-
posits were generally considered unlikely in a non-FD kidney.
On the other hand, light microscopy can identify FD-related
kidney changes.11 The strengths of the study are that it was a
multicenter design, had no dropouts to follow-up, and ap-
plied regular multidisciplinary patient assessments; the study
also included the complete collection of clinical, biochemical,
genetic, and phenotypic information; data on the immunogenic
pretransplantation risk; and regular and serial KTx biopsies.
These advantages were frequently lacking in other studies. Im-
portantly, this study used awell-matched non-FD control group
that was also exposed to the same environmental conditions be-
cause of medical treatment and geographic and cultural prox-
imities of the FD and non-FD recipients. As Fabry patients
requiring transplantation are generally younger than the overall
transplant patient population and, on that basis, might be ex-
pected to have better outcomes, we have used an age-matched
control group to avoid this potential bias. Because it is not suf-
ficient to match age and sex to reach an equal start line, we also
matched according to the immunosuppression era, number of
transplants, and presence of DSA and HLA mismatches.CONCLUSIONS
In conclusion, the study shows similar graft survival and
superior death-censored graft survival in FD patients com-
pared with non-FD matched controls. ERT may improveCopyright © 2018 Wolters Kluwerpatient survival and protect kidney grafts from invasion of
host cells containingGb3 deposits. Finally, the study data fur-
ther support KTx in FD only using a screened-negative donor
for FD.ACKNOWLEDGMENT
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(Recurrence of Fabry’s disease in a renal allograft 14 years af-
ter transplantation, Nephrol Dial Transplant, 1995 Volume
10 pages 287-289) by permission of Oxford University Press.
REFERENCES
1. Desnick R, Ioannou Y, Eng C. α-Galactosidase A deficiency: Fabry dis-
ease. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The Metabolic
and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:
3733–3774.
2. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine
is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:
2812–2817.
3. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progres-
sion of nephropathy, and prevalence of cardiac and cerebrovascular
events before enzyme replacement therapy. Nephrol Dial Transplant.
2009;24:2102–2111.
4. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-
recognized multisystemic disorder: expert recommendations for diag-
nosis, management, and enzyme replacement therapy. Ann Intern Med.
2003;138:338–346.
5. vonScheidtW, EngCM, Fitzmaurice TF, et al. An atypical variant of Fabry's
disease with manifestations confined to the myocardium. N Engl J Med.
1991;324:395–399.
6. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undi-
agnosed hemodialysis patients and identification of a "renal variant" phe-
notype. Kidney Int. 2003;64:801–807.
7. Shabbeer J, Yasuda M, Benson SD, et al. Fabry disease: identification of
50 novel alpha-galactosidase A mutations causing the classic phenotype
and three-dimensional structural analysis of 29 missense mutations. Hum
Genomics. 2006;2:297–309.
8. Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination
of presence of Fabry disease in women results in 40% false-negative re-
sults. J Am Coll Cardiol. 2008;51:2082; author reply 2082-2083.
9. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in
female patients with Fabry disease. Clin Genet. 2016;89:44–54.
10. Branton M, Schiffmann R, Kopp JB. Natural history and treatment of
renal involvement in Fabry disease. J Am Soc Nephrol. 2002;13(Suppl 2):
S139–S143.
11. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc
Nephrol. 2002;13(Suppl 2):S134–S138.
12. Bühler FR, Thiel G, Dubach UC, et al. Kidney transplantation in Fabry's
disease. Br Med J. 1973;3:28–29.
13. Maizel SE, Simmons RL, Kjellstrand C, et al. Ten-year experience in renal
transplantation for Fabry's disease. Transplant Proc. 1981;13(1 Pt 1):
57–59.
14. Ojo A, Meier-Kriesche HU, Friedman G, et al. Excellent outcome of renal
transplantation in patients with Fabry's disease. Transplantation. 2000;
69:2337–2339.
15. Inderbitzin D, Avital I, Largiader F, et al. Kidney transplantation improves
survival and is indicated in Fabry's disease. Transplant Proc. 2005;37:
4211–4214.
16. Shah T, Gill J, Malhotra N, et al. Kidney transplant outcomes in patients
with Fabry disease. Transplantation. 2009;87:280–285.
17. Obrador GT, Ojo A, Thadhani R. End-stage renal disease in patients with
Fabry disease. J Am Soc Nephrol. 2002;13(Suppl 2):S144–S146.
18. Cybulla M, Walter KN, Schwarting A, et al. Kidney transplantation in pa-
tients with Fabry disease. Transpl Int. 2009;22:475–481.
19. Terryn W, Cochat P, Froissart R, et al. Fabry nephropathy: indications for
screening and guidance for diagnosis and treatment by the European
Renal Best Practice. Nephrol Dial Transplant. 2013;28:505–517.
20. Clarke JT, Guttmann RD, Wolfe LS, et al. Enzyme replacement therapy
by renal allotransplantation in Fabry's disease. N Engl J Med. 1972;287:
1215–1218.
21. Faraggiana T, Churg J, Grishman E, et al. Light- and electron-microscopic
histochemistry of Fabry's disease. Am J Pathol. 1981;103:247–262. Health, Inc. All rights reserved.
© 2018 Wolters Kluwer Ersözlü et al 193322. Friedlaender MM, Kopolovic J, Rubinger D, et al. Renal biopsy in Fabry's
disease eight years after successful renal transplantation. Clin Nephrol.
1987;27:206–211.
23. McMahon J, Tubbs R, Gephardt G, Steinmuller D. Pseudo-Reoccurence
of Fabry’s Disease in renal allograft. Paper presented at: LABORATORY
INVESTIGATION. 1986.
24. Nowak A, Koch G, Huynh-Do U, et al. Disease progression modeling to
evaluate the effects of enzyme replacement therapy on kidney function
in adult patients with the classic phenotype of Fabry disease. Kidney
Blood Press Res. 2017;42:1–15.
25. EBPG Expert Group on Renal Transplantation. European best practice
guidelines for renal transplantation. Section IV: Long-term management
of the transplant recipient. IV.13 Analysis of patient and graft survival.
Nephrol Dial Transplant. 2002;17(Suppl 4):60–67.
26. Wehmeier C, Georgalis A, Hirt-Minkowski P, et al. 2222 kidney transplan-
tations at the University Hospital Basel: a story of success and new chal-
lenges. Swiss Med Wkly. 2016;146:w14317.
27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glo-
merular filtration rate. Ann Intern Med. 2009;150:604–612.
28. Gantenbein H, Bruder E, Burger HR, et al. Recurrence of Fabry's disease
in a renal allograft 14 years after transplantation. Nephrol Dial Transplant.
1995;10:287–289.
29. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant
human alpha-galactosidase A—replacement therapy in Fabry's disease.
N Engl J Med. 2001;345:9–16.
30. Weidemann F, Niemann M, Stork S, et al. Long-term outcome of enzyme-
replacement therapy in advanced Fabry disease: evidence for disease pro-
gression towards serious complications. J Intern Med. 2013;274:331–341.
31. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for ad-
vanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77–86.
32. Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme
replacement therapy with agalsidase beta in patients with Fabry disease.
J Med Genet. 2015;52:353–358.
33. Tsakiris D, SimpsonHK, Jones EH, et al. Report onmanagement of renale
failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy
in the ERA-EDTA Registry.Nephrol Dial Transplant. 1996;11(Suppl 7):4–20.
34. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialy-
sis in the United States. Kidney Int. 2002;61:249–255.
35. Clement M, McGonigle RJ, Monkhouse PM, et al. Renal transplantation in
Anderson-Fabry disease. J R Soc Med. 1982;75:557–560.
36. Bannwart F. Fabry's disease. Light and electron microscopic cardiac find-
ings 12 years after successful kidney transplantation. Schweiz Med
Wochenschr. 1982;112:1742–1747.
37. Popli S, Molnar ZV, Leehey DJ, et al. Involvement of renal allograft by
Fabry's disease. Am J Nephrol. 1987;7:316–318.
38. Mosnier JF, Degott C, Bedrossian J, et al. Recurrence of Fabry's disease
in a renal allograft eleven years after successful renal transplantation.
Transplantation. 1991;51:759–762.
39. Erten Y, Ozdemir FN, Demirhan B, et al. A case of Fabry's disease with
normal kidney function at 10 years after successful renal transplantation.
Transplant Proc. 1998;30:842–843.
40. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there func-
tional consequences? Exp Biol Med (Maywood). 2001;226:825–830.Copyright © 2018 Wolters Kluwer H41. SakurabaH, Tsukimura T, Tanaka T, et al. Clinical and biochemical investiga-
tion of male patients exhibitingmembranous cytoplasmic bodies in biopsied
kidney tissues; a pitfall in diagnosis of Fabry disease. J Nephropathol.
2015;4:91–96.
42. Bracamonte ER, Kowalewska J, Starr J, et al. Iatrogenic phospholipidosis
mimicking Fabry disease. Am J Kidney Dis. 2006;48:844–850.
43. de Menezes Neves PDM, Machado JR, Custodio FB, et al. Ultrastructural
deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?
comparative case reports. BMC Nephrol. 2017;18:157.
44. Albay D, Adler SG, Philipose J, et al. Chloroquine-induced lipidosis mim-
icking Fabry disease. Mod Pathol. 2005;18:733–738.
45. Muller-Hocker J, Schmid H, Weiss M, et al. Chloroquine-induced
phospholipidosis of the kidney mimicking Fabry's disease: case report
and review of the literature. Hum Pathol. 2003;34:285–289.
46. Pintavorn P, Cook WJ. Progressive renal insufficiency associated with
amiodarone-induced phospholipidosis. Kidney Int. 2008;74:1354–1357.
47. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: drug-
induced lipid storage disease. Arch Ophthalmol. 1981;99:257–261.
48. Scheurle C, DammrichM, Becker JU, et al. Renal phospholipidosis possi-
bly induced by ranolazine. Clin Kidney J. 2014;7:62–64.
49. Filippone EJ, Carson JM, Beckford RA, et al. Sirolimus-induced pneumo-
nitis complicated by pentamidine-induced phospholipidosis in a renal
transplant recipient: a case report. Transplant Proc. 2011;43:2792–2797.
50. Munic V, Banjanac M, Kostrun S, et al. Intensity of macrolide anti-
inflammatory activity in J774A.1 cells positively correlates with cellular ac-
cumulation and phospholipidosis. Pharmacol Res. 2011;64:298–307.
51. Banks DE, Milutinovic J, Desnick RJ, et al. Silicon nephropathy mimicking
Fabry's disease. Am J Nephrol. 1983;3:279–284.
52. Desnick RJ, Allen KY, Simmons RL, et al. Fabry disease: correction of the
enzymatic deficiency by renal transplantation. Birth Defects Orig Artic Ser.
1973;9:88–96.
53. Wang AM, Desnick RJ. Structural organization and complete sequence of
the human alpha-N-acetylgalactosaminidase gene: homology with the
alpha-galactosidase A gene provides evidence for evolution from a com-
mon ancestral gene. Genomics. 1991;10:133–142.
54. WangAM,BishopDF,DesnickRJ.Humanalpha-N-acetylgalactosaminidase-
molecular cloning, nucleotide sequence, and expression of a full-length
cDNA. Homology with human alpha-galactosidase A suggests evolution
from a common ancestral gene. J Biol Chem. 1990;265:21859–21866.
55. Ramos EL, Tisher CC. Recurrent diseases in the kidney transplant. Am
J Kidney Dis. 1994;24:142–154.
56. Bollée G, Cochat P, Daudon M. Recurrence of crystalline nephropathy af-
ter kidney transplantation in APRT deficiency and primary hyperoxaluria.
Can J Kidney Health Dis. 2015;2:31.
57. Rudnicki M. FSGS Recurrence in Adults after Renal Transplantation.
Biomed Res Int. 2016;2016:3295618.
58. Paull LS, Lipinski MJ, Wilson WG, et al. Female with Fabry Disease Un-
knowingly Donates Affected Kidney to Sister: A Call for Pre-transplant Ge-
netic Testing. JIMD reports. 2012;4:1–4.
59. Odani K, Okumi M, Honda K, et al. Kidney transplantation from a mother
with unrecognized Fabry disease to her son with low α-galactosidase
A activity: A 14-year follow-up without enzyme replacement therapy.
Nephrology (Carlton). 2016;21(Suppl 1):57–59.ealth, Inc. All rights reserved.
